« Return to News | Drug Sponsors | R&D Trends

Genzyme sells pharmaceuticals segment

Monday, March 7, 2011 10:49 AM

Cambridge, Mass.-based Genzyme has completed the sale of its pharmaceutical intermediates business to Germany's International Chemical Investors Group for an undisclosed amount, according to BIOSmartBrief.

Genzyme said selling the unit will allow it to focus on its core businesses.  ICIG acquired all of Genzyme's pharmaceutical intermediates business excluding drug delivery technologies.

Approximately 120 Genzyme workers will remain employed by the new business, which will be called Corden Pharma Switzerland.

Corden Pharma has offices in Switzerland and Boston and will supply Genzyme with materials needed to produce eliglustat tartrate, an investigational treatment for Gaucher disease type 1 currently in phase III clinical trials. Corden will also supply materials needed for other treatments.

Genzyme announced last month it would be acquired by French drugmaker Sanofi-aventis.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.